April 26, 2018
|
||||
Date of Report (Date of earliest event reported)
|
||||
NU SKIN ENTERPRISES, INC.
|
||||
(Exact name of registrant as specified in its charter)
|
||||
Delaware
|
001-12421
|
87-0565309
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
||
75 West Center Street
Provo, Utah 84601
|
||||
(Address of principal executive offices and zip code)
|
||||
(801) 345-1000
|
||||
(Registrant's telephone number, including area code)
|
||||
N/A
|
||||
(Former name or former address, if changed since last report)
|
□ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
□ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Item 9.01 |
Financial Statements and Exhibits.
|
Revenue:
|
$616.2 million, +24%
· +7% fx impact
|
Earnings Per Share (EPS):
|
$0.64, which includes a $0.12 negative impact associated with the settlement of a convertible note and a $0.03 charge from purchase accounting, compared to $0.51
|
Sales Leaders:
|
63,500, +16%
|
Customers:
|
1,086,000, +11%
|
Revenue:
|
$616.2 million compared to $499.1 million
|
Gross Margin:
|
76.3% compared to 77.7%
· Gross margin of core Nu Skin business was 77.9%
|
Selling Expenses:
|
41.8% of revenue compared to 41.9%
|
G&A Expenses:
|
24.9% of revenue compared to 26.6%
|
Operating Margin:
|
9.6% compared to 9.3%
|
Other Income / (Expense):
|
$1.2 million income compared to ($4.6) million expense
|
Income Tax Rate:
|
41.0% compared to 34.1%
|
EPS:
|
$0.64, which includes a $0.12 impact associated with the settlement of a convertible note and a $0.03 charge from purchase accounting, compared to $0.51
|
Dividend Payments:
|
$19.8 million
|
Stock Repurchases:
|
$17.4 million; $110.6 million remaining in authorization
|
Q2 2018 Revenue:
|
$630 to $650 million, 15% to 18% growth
· Approximately +5% fx impact
|
Q2 2018 EPS:
|
$0.86 to $0.91 which includes an estimated $0.05 purchase accounting charge
|
2018 Revenue:
|
$2.51 billion to $2.56 billion, 10% to 12% growth
· Approximately +3% fx impact
|
2018 EPS
|
$3.45 to $3.65 which includes the first quarter $0.12 convertible note impact and an estimated $0.16 purchase accounting charge for the year
|
·
|
adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
|
·
|
risk that direct selling laws and regulations in any of our markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to our business model or negatively impacts our revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;
|
·
|
any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
|
·
|
risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
|
·
|
uncertainties regarding the future financial performance of the company's recent acquisitions;
|
·
|
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
|
·
|
regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
|
·
|
unpredictable economic conditions and events globally;
|
·
|
uncertainties related to interpretation of, and forthcoming regulations under, the recently enacted U.S. tax reform legislation; the company's future tax-planning initiatives; any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
|
·
|
continued competitive pressures in the company's markets.
|
2018
|
2017
|
%
Change
|
Constant Currency
% Change
|
|||||||||||||
Mainland China
|
$
|
197,531
|
$
|
150,004
|
32%
|
|
22%
|
|
||||||||
Americas/Pacific
|
92,289
|
71,425
|
29%
|
|
32%
|
|
||||||||||
South Korea
|
88,930
|
82,471
|
8%
|
|
1%
|
|
||||||||||
Southeast Asia
|
70,860
|
63,025
|
12%
|
|
7%
|
|
||||||||||
Japan
|
63,224
|
61,156
|
3%
|
|
(2%)
|
|
||||||||||
EMEA
|
44,981
|
34,064
|
32%
|
|
15%
|
|
||||||||||
Hong Kong/Taiwan
|
40,992
|
35,948
|
14%
|
|
11%
|
|
||||||||||
Other
|
17,412
|
1,006
|
1,631%
|
|
1,631%
|
|
||||||||||
Total
|
$
|
616,219
|
$
|
499,099
|
24%
|
|
17%
|
|
2018
|
2017
|
% Increase
(Decrease)
|
||||||||||||||||||||||
Customers
|
Sales Leaders
|
Customers
|
Sales Leaders
|
Customers
|
Sales Leaders
|
|||||||||||||||||||
Mainland China
|
200,000
|
27,000
|
176,000
|
19,100
|
14%
|
|
41%
|
|
||||||||||||||||
Americas/Pacific
|
246,000
|
8,200
|
191,000
|
6,900
|
29%
|
|
19%
|
|
||||||||||||||||
South Korea
|
179,000
|
7,300
|
189,000
|
8,000
|
(5%)
|
|
(9%)
|
|
||||||||||||||||
Southeast Asia
|
118,000
|
6,600
|
98,000
|
6,200
|
20%
|
|
6%
|
|
||||||||||||||||
Japan
|
129,000
|
6,200
|
132,000
|
6,400
|
(2%)
|
|
(3%)
|
|
||||||||||||||||
EMEA
|
142,000
|
4,300
|
124,000
|
4,100
|
15%
|
|
5%
|
|
||||||||||||||||
Hong Kong/Taiwan
|
72,000
|
3,900
|
70,000
|
3,900
|
3%
|
|
—
|
|||||||||||||||||
Total
|
1,086,000
|
63,500
|
980,000
|
54,600
|
11%
|
|
16%
|
|
NU SKIN ENTERPRISES, INC.
|
||||||||
Consolidated Statements of Income (Unaudited)
|
||||||||
For the First Quarters Ended March 31, 2018 and 2017
|
||||||||
(in thousands, except per share amounts)
|
||||||||
2018
|
2017
|
|||||||
Revenue
|
$
|
616,219
|
$
|
499,099
|
||||
Cost of sales
|
146,281
|
111,266
|
||||||
Gross profit
|
469,938
|
387,833
|
||||||
Operating expenses:
|
||||||||
Selling expenses
|
257,702
|
209,008
|
||||||
General and administrative expenses
|
153,246
|
132,563
|
||||||
Total operating expenses
|
410,948
|
341,571
|
||||||
Operating income
|
58,990
|
46,262
|
||||||
Other income (expense), net
|
1,207
|
(4,567
|
)
|
|||||
Income before provision for income taxes
|
60,197
|
41,695
|
||||||
Provision for income taxes
|
24,658
|
14,206
|
||||||
Net income
|
$
|
35,539
|
$
|
27,489
|
||||
Net income per share:
|
||||||||
Basic
|
$
|
0.66
|
$
|
0.52
|
||||
Diluted
|
$
|
0.64
|
$
|
0.51
|
||||
Weighted average common shares outstanding:
|
||||||||
Basic
|
53,997
|
52,678
|
||||||
Diluted
|
55,959
|
54,057
|
NU SKIN ENTERPRISES, INC.
|
||||||||
Consolidated Balance Sheets (Unaudited)
|
||||||||
(in thousands)
|
||||||||
March 31,
2018
|
December 31,
2017
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
421,484
|
$
|
426,399
|
||||
Current investments
|
8,615
|
11,847
|
||||||
Accounts receivable
|
54,014
|
33,196
|
||||||
Inventories, net
|
282,983
|
253,454
|
||||||
Prepaid expenses and other
|
66,705
|
52,893
|
||||||
833,801
|
777,789
|
|||||||
Property and equipment, net
|
508,476
|
464,587
|
||||||
Goodwill
|
187,423
|
114,954
|
||||||
Other intangible assets, net
|
100,601
|
67,647
|
||||||
Other assets
|
144,368
|
164,895
|
||||||
Total assets
|
$
|
1,774,669
|
$
|
1,589,872
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
62,253
|
$
|
50,341
|
||||
Accrued expenses
|
309,536
|
319,189
|
||||||
Current portion of long-term debt
|
362,659
|
77,840
|
||||||
734,448
|
447,370
|
|||||||
Long-term debt
|
107,275
|
310,790
|
||||||
Other liabilities
|
133,818
|
127,116
|
||||||
Total liabilities
|
975,541
|
885,276
|
||||||
Stockholders' equity:
|
||||||||
Class A common stock
|
91
|
91
|
||||||
Additional paid-in capital
|
523,233
|
466,349
|
||||||
Treasury stock, at cost
|
(1,280,586
|
)
|
(1,304,694
|
)
|
||||
Accumulated other comprehensive loss
|
(55,474
|
)
|
(66,318
|
)
|
||||
Retained earnings
|
1,611,864
|
1,609,168
|
||||||
799,128
|
704,596
|
|||||||
Total liabilities and stockholders' equity
|
$
|
1,774,669
|
$
|
1,589,872
|